Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbrc.2020.11.095 http://scihub22266oqcxt.onion/10.1016/j.bbrc.2020.11.095 33309272!7713548!33309272     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33309272.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Biochem+Biophys+Res+Commun 2021 ; 538 (ä): 173-179 Nephropedia Template TP {{tp|p=33309272|t=2021. Identification of antiviral antihistamines for COVID-19 repurposing |pdf=|usr=}}{{33309272}} gab.com Text Identification of antiviral antihistamines for COVID-19 repurposing JO: Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33309272 #FOAvip There is an urgent need to identify therapies that prevent SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Although repurposed drugs with favorable safety profiles could have significant benefit, widely available prevention or treatment options for COVID-19 have yet to be identified. Efforts to identify approved drugs with in vitro activity against SARS-CoV-2 resulted in identification of antiviral sigma-1 receptor ligands, including antihistamines in the histamine-1 receptor binding class. We identified antihistamine candidates for repurposing by mining electronic health records of usage in population of more than 219,000 subjects tested for SARS-CoV-2. Usage of diphenhydramine, hydroxyzine and azelastine was associated with reduced incidence of SARS-CoV-2 positivity in subjects greater than age 61. We found diphenhydramine, hydroxyzine and azelastine to exhibit direct antiviral activity against SARS-CoV-2 in vitro. Although mechanisms by which specific antihistamines exert antiviral effects is not clear, hydroxyzine, and possibly azelastine, bind Angiotensin Converting Enzyme-2 (ACE2) and the sigma-1 receptor as off-targets. Clinical studies are needed to measure the effectiveness of diphenhydramine, hydroxyzine and azelastine for disease prevention, for early intervention, or as adjuvant therapy for severe COVID-19. Twit Text FOAVip Identification of antiviral antihistamines for COVID-19 repurposing ????Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33309272 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33309272 #FOAvip English Wikipedia <ref>{{Cite pmid|33309272}}</ref> Identification of antiviral antihistamines for COVID-19 repurposing #MMPMID33309272 Reznikov LR; Norris MH; Vashisht R; Bluhm AP; Li D; Liao YJ; Brown A; Butte AJ; Ostrov DA Biochem Biophys Res Commun 2021[Jan]; 538 (ä): 173-179 PMID33309272show ga There is an urgent need to identify therapies that prevent SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Although repurposed drugs with favorable safety profiles could have significant benefit, widely available prevention or treatment options for COVID-19 have yet to be identified. Efforts to identify approved drugs with in vitro activity against SARS-CoV-2 resulted in identification of antiviral sigma-1 receptor ligands, including antihistamines in the histamine-1 receptor binding class. We identified antihistamine candidates for repurposing by mining electronic health records of usage in population of more than 219,000 subjects tested for SARS-CoV-2. Usage of diphenhydramine, hydroxyzine and azelastine was associated with reduced incidence of SARS-CoV-2 positivity in subjects greater than age 61. We found diphenhydramine, hydroxyzine and azelastine to exhibit direct antiviral activity against SARS-CoV-2 in vitro. Although mechanisms by which specific antihistamines exert antiviral effects is not clear, hydroxyzine, and possibly azelastine, bind Angiotensin Converting Enzyme-2 (ACE2) and the sigma-1 receptor as off-targets. Clinical studies are needed to measure the effectiveness of diphenhydramine, hydroxyzine and azelastine for disease prevention, for early intervention, or as adjuvant therapy for severe COVID-19. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |Angiotensin-Converting Enzyme 2/*chemistry/genetics/metabolism[MESH] |Animals[MESH] |Antiviral Agents/*chemistry/pharmacology/therapeutic use[MESH] |Catalytic Domain[MESH] |Chlorocebus aethiops[MESH] |HEK293 Cells[MESH] |Histamine Antagonists/*chemistry/pharmacology/therapeutic use[MESH] |Humans[MESH] |Ligands[MESH] |Protein Binding[MESH] |Receptors, Histamine/chemistry[MESH] |Receptors, sigma/chemistry[MESH] |SARS-CoV-2/*drug effects[MESH] |Sigma-1 Receptor[MESH]Identification of antiviral antihistamines for COVID-19 repurposing (epmc).pdf DeepDyve Pubget Overpricing